We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+35.17%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$53.7M
Cap. Flow
-$13.3M
Cap. Flow %
-3.1%
Top 10 Hldgs %
66.36%
Holding
57
New
–
Increased
1
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$5.62M

Top Sells

Rank Stock Value
1
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$6.6M
2
IMCR icon
Immunocore
IMCR
+$3.81M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.65M
4
HLVX
HilleVax
HLVX
+$2.22M
5
RXRX icon
Recursion Pharmaceuticals
RXRX
+$2.18M

Sector Composition

Rank Sector Weight
1 Healthcare 98.01%
2 Financials 1.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRON
51
DELISTED
Kronos Bio
KRON
$262K 0.06%
78,131
– –
ATXS
52
DELISTED
Astria Therapeutics
ATXS
$226K 0.05%
25,000
– –
NGM
53
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$179K 0.04%
13,669
– –
KALA icon
54
KALA BIO
KALA
$14.5M
$132K 0.03%
240
-1
-0.4% -$785
NUVB.WS
55
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$27K 0.01%
133,333
– –
SRZNW icon
56
Surrozen Inc Warrant
SRZNW
$8.86K
$18K ﹤0.01%
99,999
– –
RXRX icon
57
Recursion Pharmaceuticals
RXRX
$1.73B
– –
-267,996
Closed -$2.18M
1 2
3

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q3 2022 Portfolio in Review

As of Q3 2022, Samsara BioCapital held 57 positions worth $429M, up 14% from $375M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Samsara BioCapital withdrew a net $13.3M in Q3 2022, closing 1 position and reducing 6 holdings. Its most notable exit was Recursion Pharmaceuticals, an estimated $2.18M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Financials.

Against the trend, Samsara BioCapital added an estimated $5.62M to Syros Pharmaceuticals, Inc. Common Stock.

  • Samsara BioCapital added most to Syros Pharmaceuticals, Inc. Common Stock in Q3 2022, an estimated $5.62M increase.
  • Samsara BioCapital's biggest Q3 2022 reduction was Forma Therapeutics Holdings, Inc. Common Stock, cutting an estimated $6.6M.
  • Samsara BioCapital fully exited Recursion Pharmaceuticals in Q3 2022, selling an estimated $2.18M.
  • Samsara BioCapital's ten largest holdings make up 66% of its $429M portfolio in Q3 2022.
  • Samsara BioCapital opened 0 new positions and closed 1 in Q3 2022.
  • Samsara BioCapital's portfolio value rose 14% quarter-over-quarter to $429M.

Based on Samsara BioCapital's 13F filing for Q3 2022, filed 14 Nov 2022.